Respiratory Drugs Market by Type and Geography - Forecast and Analysis 2022-2026
- Published: Apr 2022
- Pages: 137
- SKU: IRTNTR73197
Enjoy complimentary customisation on priority with our Enterprise License!
Single:
One user only.
Quick & easy download optionEnterprise:
Unlimited user access (Within your organization)
Complimentary Customization Included
The respiratory drugs market share is expected to increase by USD 26.95 billion from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 5.96%.
This respiratory drugs market research report provides valuable insights on the post-COVID-19 impact on the market, which will help companies evaluate their business approaches. Furthermore, this report extensively covers respiratory drugs market segmentation by type (asthma, COPD, allergic rhinitis, cystic fibrosis, and other respiratory diseases) and geography (North America, Europe, Asia, and Rest of World (ROW)). The respiratory drugs market report also offers information on several market vendors, including Abbott Laboratories, AbbVie Inc., Aerogen Pharma Ltd., AstraZeneca Plc, Aurobindo Pharma Ltd., Boehringer Ingelheim International GmbH, Celon Pharma SA, Cipla Ltd., F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, Glenmark Pharmaceuticals Ltd., Laboratory Corp. of America Holdings, Lupin Ltd., Medisol Lifescience Pvt. Ltd., Merck and Co. Inc., Novartis AG, Sumitomo Pharma Co. Ltd., Teva Pharmaceutical Industries Ltd., Vertex Pharmaceuticals Inc., and Wellona Pharma among others.
What will the Respiratory Drugs Market Size be During the Forecast Period?
Download the Free Report Sample to Unlock the Respiratory Drugs Market Size for the Forecast Period and Other Important Statistics
Respiratory Drugs Market: Key Drivers, Trends, and Challenges
The need for sustainable and safe respiratory drugs is notably driving the respiratory drugs market growth, although factors such as the high cost of conducting clinical trials in respiratory disorders may impede the market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the respiratory drugs industry. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.
Key Respiratory Drugs Market Driver
One of the key factors driving the global respiratory drugs industry growth is the need for sustainable and safe respiratory drugs. Globally, respiratory diseases are the leading cause of death, with COPD as the third cause of death in western Europe and the fourth globally. Despite the presence of effective therapies, numerous patients globally live with poorly controlled respiratory diseases and have a low quality of life. Over the past 40 years, there have been a few new classes of drug therapy introduced for the treatment of respiratory diseases. Leukotriene receptor antagonists are a new class of drugs, but these drugs are not adequately effective in controlling asthma. Overall, drug innovation in respiratory medicine is a pressing issue and will drive market growth during the forecast period.
Key Respiratory Drugs Market Trend
High cost of respiratory disease management is one of the key respiratory drugs market trends that is expected to impact the industry positively in the forecast period. Respiratory diseases are a huge burden globally in terms of direct health services costs and indirect costs related to prescribed drugs. The high cost of respiratory disease management has led organizations such as the Lung Foundation Australia to demand support and funding from the government to reduce the cost burden on patients. Moreover, the economic burden of respiratory diseases can be reduced with access to preventive care and early treatment. The British Lung Foundation and the British Thoracic Society opine that cost-effective approaches for the management of respiratory diseases are self-management and patient education. Such factors will further support the market growth in the coming years.
Key Respiratory Drugs Market Challenge
One of the key challenges to the global respiratory drugs industry growth is the high cost of conducting clinical trials in respiratory disorders. The incidence of disease in this class has increased rapidly in recent years. According to ClinicalTrials.gov, there are few clinical trial studies of respiratory diseases. There are around 88 active and recruiting Phase I study for asthma treatment and 39 studies for COPD. The cost associated with each phase of a clinical trial restricts the number of clinical trial studies. Approximately USD 115.3 million is spent for each phase of a clinical trial, which includes Phase I, II, III, and IV. Respiratory system studies ranked third in terms of cost spent per a study in clinical trials. Such factors may challenge the market growth in the forecast years.
This respiratory drugs market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2022-2026.
Parent Market Analysis
Technavio categorizes the global respiratory drugs market as a part of the pharmaceutical market. Our research report has extensively covered external factors influencing the parent market growth potential in the coming years, which will determine the levels of growth of the respiratory drugs market during the forecast period.
Who are the Major Respiratory Drugs Market Vendors?
The report analyzes the market's competitive landscape and offers information on several market vendors, including:
- Abbott Laboratories
- AbbVie Inc.
- Aerogen Pharma Ltd.
- AstraZeneca Plc
- Aurobindo Pharma Ltd.
- Boehringer Ingelheim International GmbH
- Celon Pharma SA
- Cipla Ltd.
- F. Hoffmann La Roche Ltd.
- GlaxoSmithKline Plc
- Glenmark Pharmaceuticals Ltd.
- Laboratory Corp. of America Holdings
- Lupin Ltd.
- Medisol Lifescience Pvt. Ltd.
- Merck and Co. Inc.
- Novartis AG
- Sumitomo Pharma Co. Ltd.
- Teva Pharmaceutical Industries Ltd.
- Vertex Pharmaceuticals Inc.
- Wellona Pharma
This statistical study of the respiratory drugs market encompasses successful business strategies deployed by the key vendors. The respiratory drugs market is fragmented and the vendors are deploying growth strategies such as investment in R and D to compete in the market.
Product Insights and News
- Abbott Laboratories - The company offers respiratory drugs such as Allerdest M and Enteroshield.
- Abbott Laboratories - In December 2021, the company appointed Robert B. Ford as Chairman of the Board.
To make the most of the opportunities and recover from the post-COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.
The respiratory drugs market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies.
Respiratory Drugs Market Value Chain Analysis
Our report provides extensive information on the value chain analysis for the respiratory drugs market, which vendors can leverage to gain a competitive advantage during the forecast period. The end-to-end understanding of the value chain is essential in profit margin optimization and evaluation of business strategies. The data available in our value chain analysis segment can help vendors drive costs and enhance customer services during the forecast period.
Which are the Key Regions of the Respiratory Drugs Market?
For more insights on the market share of various regions Request for a FREE sample now!
50% of the market's growth will originate from North America during the forecast period. US and Canada are the key markets for respiratory drugs in North America. Market growth in this region will be faster than the growth of the market in Europe and ROW.
The presence of top players such as Genentech (Roche) and Merck and the recent launch of new disease-modifying therapies will facilitate the respiratory drugs market growth in North America over the forecast period. This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.
COVID Impact and Recovery Analysis
A rise in the number of COVID-19 cases in the first quarter of 2020 led to partial lockdowns in several countries, including Canada and Mexico. Thus, some scheduled treatments were either delayed or postponed, which thus declined the adoption of various drugs, such as respiratory drugs, and impacted market growth in 2020 and Q1 2021 to some extent. However, by January 2021, following the widespread COVID-19 vaccination drive, lockdown restrictions in various countries were somewhat relaxed, which led to the resumption of business activities. Thus, this is expected to increase the demand in the respiratory drugs market in North America during the forecast period.
What are the Revenue-generating Type Segments in the Respiratory Drugs Market?
To gain further insights on the market contribution of various segments Request for a FREE sample
The respiratory drugs market share growth in the asthma segment will be significant during the forecast period. The growth is attributed to the significant increase in the prevalence of asthma globally. Approximately 300 million people worldwide currently have asthma, and its prevalence increases by 50% every decade. Thus, leading vendors such as AstraZeneca and Novartis are expected to launch new drugs in the coming years to tap the huge market potential for asthma.
This report provides an accurate prediction of the contribution of all the segments to the growth of the respiratory drugs market size and actionable market insights on the post-COVID-19 impact on each segment.
|
Respiratory Drugs Market Scope |
|
|
Report Coverage |
Details |
|
Page number |
120 |
|
Base year |
2021 |
|
Forecast period |
2022-2026 |
|
Growth momentum & CAGR |
Accelerate at a CAGR of 5.96% |
|
Market growth 2022-2026 |
$ 26.95 billion |
|
Market structure |
Fragmented |
|
YoY growth (%) |
5.15 |
|
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
|
Performing market contribution |
North America at 50% |
|
Key consumer countries |
US, Canada, Germany, UK, and China |
|
Competitive landscape |
Leading companies, Competitive strategies, Consumer engagement scope |
|
Key companies profiled |
Abbott Laboratories, AbbVie Inc., Aerogen Pharma Ltd., AstraZeneca Plc, Aurobindo Pharma Ltd., Boehringer Ingelheim International GmbH, Celon Pharma SA, Cipla Ltd., F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, Glenmark Pharmaceuticals Ltd., Laboratory Corp. of America Holdings, Lupin Ltd., Medisol Lifescience Pvt. Ltd., Merck and Co. Inc., Novartis AG, Sumitomo Pharma Co. Ltd., Teva Pharmaceutical Industries Ltd., Vertex Pharmaceuticals Inc., and Wellona Pharma |
|
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the forecast period. |
|
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
What are the Key Data Covered in this Respiratory Drugs Market Report?
- CAGR of the market during the forecast period 2022-2026
- Detailed information on factors that will drive respiratory drugs market growth during the next five years
- Precise estimation of the respiratory drugs market size and its contribution to the parent market
- Accurate predictions on upcoming trends and changes in consumer behavior
- The growth of the respiratory drugs industry across North America, Europe, Asia, and Rest of World (ROW)
- A thorough analysis of the market's competitive landscape and detailed information on vendors
- Comprehensive details of factors that will challenge the growth of respiratory drugs market vendors
We can help! Our analysts can customize this report to meet your requirements. Get in touch
1 Executive Summary
- 1.1 Market overview
- Exhibit 01: Executive Summary – Chart on Market Overview
- Exhibit 02: Executive Summary – Data Table on Market Overview
- Exhibit 03: Executive Summary – Chart on Global Market Characteristics
- Exhibit 04: Executive Summary – Chart on Market by Geography
- Exhibit 05: Executive Summary – Chart on Market Segmentation by Type
- Exhibit 06: Executive Summary – Chart on Incremental Growth
- Exhibit 07: Executive Summary – Data Table on Incremental Growth
- Exhibit 08: Executive Summary – Chart on Vendor Market Positioning
2 Market Landscape
- 2.1 Market ecosystem
- Exhibit 09: Parent market
- Exhibit 10: Market Characteristics
3 Market Sizing
- 3.1 Market definition
- Exhibit 11: Offerings of vendors included in the market definition
- 3.2 Market segment analysis
- Exhibit 12: Market segments
- 3.3 Market size 2021
- 3.4 Market outlook: Forecast for 2021-2026
- Exhibit 13: Chart on Global - Market size and forecast 2021-2026 ($ billion)
- Exhibit 14: Data Table on Global - Market size and forecast 2021-2026 ($ billion)
- Exhibit 15: Chart on Global Market: Year-over-year growth 2021-2026 (%)
- Exhibit 16: Data Table on Global Market: Year-over-year growth 2021-2026 (%)
4 Five Forces Analysis
- 4.1 Five forces summary
- Exhibit 17: Five forces analysis - Comparison between2021 and 2026
- 4.2 Bargaining power of buyers
- Exhibit 18: Chart on Bargaining power of buyers – Impact of key factors 2021 and 2026
- 4.3 Bargaining power of suppliers
- Exhibit 19: Bargaining power of suppliers – Impact of key factors in 2021 and 2026
- 4.4 Threat of new entrants
- Exhibit 20: Threat of new entrants – Impact of key factors in 2021 and 2026
- 4.5 Threat of substitutes
- Exhibit 21: Threat of substitutes – Impact of key factors in 2021 and 2026
- 4.6 Threat of rivalry
- Exhibit 22: Threat of rivalry – Impact of key factors in 2021 and 2026
- 4.7 Market condition
- Exhibit 23: Chart on Market condition - Five forces 2021 and 2026
5 Market Segmentation by Type
- 5.1 Market segments
- Exhibit 24: Chart on Type - Market share 2021-2026 (%)
- Exhibit 25: Data Table on Type - Market share 2021-2026 (%)
- 5.2 Comparison by Type
- Exhibit 26: Chart on Comparison by Type
- Exhibit 27: Data Table on Comparison by Type
- 5.3 Asthma - Market size and forecast 2021-2026
- Exhibit 28: Chart on Asthma - Market size and forecast 2021-2026 ($ billion)
- Exhibit 29: Data Table on Asthma - Market size and forecast 2021-2026 ($ billion)
- Exhibit 30: Chart on Asthma - Year-over-year growth 2021-2026 (%)
- Exhibit 31: Data Table on Asthma - Year-over-year growth 2021-2026 (%)
- 5.4 COPD - Market size and forecast 2021-2026
- Exhibit 32: Chart on COPD - Market size and forecast 2021-2026 ($ billion)
- Exhibit 33: Data Table on COPD - Market size and forecast 2021-2026 ($ billion)
- Exhibit 34: Chart on COPD - Year-over-year growth 2021-2026 (%)
- Exhibit 35: Data Table on COPD - Year-over-year growth 2021-2026 (%)
- 5.5 Allergic rhinitis - Market size and forecast 2021-2026
- Exhibit 36: Chart on Allergic rhinitis - Market size and forecast 2021-2026 ($ billion)
- Exhibit 37: Data Table on Allergic rhinitis - Market size and forecast 2021-2026 ($ billion)
- Exhibit 38: Chart on Allergic rhinitis - Year-over-year growth 2021-2026 (%)
- Exhibit 39: Data Table on Allergic rhinitis - Year-over-year growth 2021-2026 (%)
- 5.6 Cystic fibrosis - Market size and forecast 2021-2026
- Exhibit 40: Chart on Cystic fibrosis - Market size and forecast 2021-2026 ($ billion)
- Exhibit 41: Data Table on Cystic fibrosis - Market size and forecast 2021-2026 ($ billion)
- Exhibit 42: Chart on Cystic fibrosis - Year-over-year growth 2021-2026 (%)
- Exhibit 43: Data Table on Cystic fibrosis - Year-over-year growth 2021-2026 (%)
- 5.7 Other respiratory diseases - Market size and forecast 2021-2026
- Exhibit 44: Chart on Other respiratory diseases - Market size and forecast 2021-2026 ($ billion)
- Exhibit 45: Data Table on Other respiratory diseases - Market size and forecast 2021-2026 ($ billion)
- Exhibit 46: Chart on Other respiratory diseases - Year-over-year growth 2021-2026 (%)
- Exhibit 47: Data Table on Other respiratory diseases - Year-over-year growth 2021-2026 (%)
- 5.8 Market opportunity by Type
- Exhibit 48: Market opportunity by Type ($ billion)
6 Customer Landscape
- 6.1 Customer landscape overview
- Exhibit 49: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
7 Geographic Landscape
- 7.1 Geographic segmentation
- Exhibit 50: Chart on Market share by geography 2021-2026 (%)
- Exhibit 51: Data Table on Market share by geography 2021-2026 (%)
- 7.2 Geographic comparison
- Exhibit 52: Chart on Geographic comparison
- Exhibit 53: Data Table on Geographic comparison
- 7.3 North America - Market size and forecast 2021-2026
- Exhibit 54: Chart on North America - Market size and forecast 2021-2026 ($ billion)
- Exhibit 55: Data Table on North America - Market size and forecast 2021-2026 ($ billion)
- Exhibit 56: Chart on North America - Year-over-year growth 2021-2026 (%)
- Exhibit 57: Data Table on North America - Year-over-year growth 2021-2026 (%)
- 7.4 Europe - Market size and forecast 2021-2026
- Exhibit 58: Chart on Europe - Market size and forecast 2021-2026 ($ billion)
- Exhibit 59: Data Table on Europe - Market size and forecast 2021-2026 ($ billion)
- Exhibit 60: Chart on Europe - Year-over-year growth 2021-2026 (%)
- Exhibit 61: Data Table on Europe - Year-over-year growth 2021-2026 (%)
- 7.5 Asia - Market size and forecast 2021-2026
- Exhibit 62: Chart on Asia - Market size and forecast 2021-2026 ($ billion)
- Exhibit 63: Data Table on Asia - Market size and forecast 2021-2026 ($ billion)
- Exhibit 64: Chart on Asia - Year-over-year growth 2021-2026 (%)
- Exhibit 65: Data Table on Asia - Year-over-year growth 2021-2026 (%)
- 7.6 Rest of World (ROW) - Market size and forecast 2021-2026
- Exhibit 66: Chart on Rest of World (ROW) - Market size and forecast 2021-2026 ($ billion)
- Exhibit 67: Data Table on Rest of World (ROW) - Market size and forecast 2021-2026 ($ billion)
- Exhibit 68: Chart on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
- Exhibit 69: Data Table on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
- 7.7 US - Market size and forecast 2021-2026
- Exhibit 70: Chart on US - Market size and forecast 2021-2026 ($ billion)
- Exhibit 71: Data Table on US - Market size and forecast 2021-2026 ($ billion)
- Exhibit 72: Chart on US - Year-over-year growth 2021-2026 (%)
- Exhibit 73: Data Table on US - Year-over-year growth 2021-2026 (%)
- 7.8 Germany - Market size and forecast 2021-2026
- Exhibit 74: Chart on Germany - Market size and forecast 2021-2026 ($ billion)
- Exhibit 75: Data Table on Germany - Market size and forecast 2021-2026 ($ billion)
- Exhibit 76: Chart on Germany - Year-over-year growth 2021-2026 (%)
- Exhibit 77: Data Table on Germany - Year-over-year growth 2021-2026 (%)
- 7.9 UK - Market size and forecast 2021-2026
- Exhibit 78: Chart on UK - Market size and forecast 2021-2026 ($ billion)
- Exhibit 79: Data Table on UK - Market size and forecast 2021-2026 ($ billion)
- Exhibit 80: Chart on UK - Year-over-year growth 2021-2026 (%)
- Exhibit 81: Data Table on UK - Year-over-year growth 2021-2026 (%)
- 7.10 China - Market size and forecast 2021-2026
- Exhibit 82: Chart on China - Market size and forecast 2021-2026 ($ billion)
- Exhibit 83: Data Table on China - Market size and forecast 2021-2026 ($ billion)
- Exhibit 84: Chart on China - Year-over-year growth 2021-2026 (%)
- Exhibit 85: Data Table on China - Year-over-year growth 2021-2026 (%)
- 7.11 Canada - Market size and forecast 2021-2026
- Exhibit 86: Chart on Canada - Market size and forecast 2021-2026 ($ billion)
- Exhibit 87: Data Table on Canada - Market size and forecast 2021-2026 ($ billion)
- Exhibit 88: Chart on Canada - Year-over-year growth 2021-2026 (%)
- Exhibit 89: Data Table on Canada - Year-over-year growth 2021-2026 (%)
- 7.12 Market opportunity by geography
- Exhibit 90: Market opportunity by geography ($ billion)
8 Drivers, Challenges, and Trends
- 8.1 Market drivers
- 8.2 Market challenges
- 8.3 Impact of drivers and challenges
- Exhibit 91: Impact of drivers and challenges in 2021 and 2026
- 8.4 Market trends
9 Vendor Landscape
- 9.1 Overview
- 9.2 Vendor landscape
- Exhibit 92: Overview on Criticality of inputs and Factors of differentiation
- 9.3 Landscape disruption
- Exhibit 93: Overview on factors of disruption
- 9.4 Industry risks
- Exhibit 94: Impact of key risks on business
10 Vendor Analysis
- 10.1 Vendors covered
- Exhibit 95: Vendors covered
- 10.2 Market positioning of vendors
- Exhibit 96: Matrix on vendor position and classification
- 10.3 Abbott Laboratories
- Exhibit 97: Abbott Laboratories - Overview
- Exhibit 98: Abbott Laboratories - Business segments
- Exhibit 99: Abbott Laboratories - Key news
- Exhibit 100: Abbott Laboratories - Key offerings
- Exhibit 101: Abbott Laboratories - Segment focus
- 10.4 AstraZeneca Plc
- Exhibit 102: AstraZeneca Plc - Overview
- Exhibit 103: AstraZeneca Plc - Product / Service
- Exhibit 104: AstraZeneca Plc - Key news
- Exhibit 105: AstraZeneca Plc - Key offerings
- 10.5 Boehringer Ingelheim International GmbH
- Exhibit 106: Boehringer Ingelheim International GmbH - Overview
- Exhibit 107: Boehringer Ingelheim International GmbH - Business segments
- Exhibit 108: Boehringer Ingelheim International GmbH - Key news
- Exhibit 109: Boehringer Ingelheim International GmbH - Key offerings
- Exhibit 110: Boehringer Ingelheim International GmbH - Segment focus
- 10.6 Celon Pharma SA
- Exhibit 111: Celon Pharma SA - Overview
- Exhibit 112: Celon Pharma SA - Business segments
- Exhibit 113: Celon Pharma SA - Key offerings
- Exhibit 114: Celon Pharma SA - Segment focus
- 10.7 F. Hoffmann La Roche Ltd.
- Exhibit 115: F. Hoffmann La Roche Ltd. - Overview
- Exhibit 116: F. Hoffmann La Roche Ltd. - Business segments
- Exhibit 117: F. Hoffmann La Roche Ltd. - Key news
- Exhibit 118: F. Hoffmann La Roche Ltd. - Key offerings
- Exhibit 119: F. Hoffmann La Roche Ltd. - Segment focus
- 10.8 GlaxoSmithKline Plc
- Exhibit 120: GlaxoSmithKline Plc - Overview
- Exhibit 121: GlaxoSmithKline Plc - Business segments
- Exhibit 122: GlaxoSmithKline Plc - Key news
- Exhibit 123: GlaxoSmithKline Plc - Key offerings
- Exhibit 124: GlaxoSmithKline Plc - Segment focus
- 10.9 Glenmark Pharmaceuticals Ltd.
- Exhibit 125: Glenmark Pharmaceuticals Ltd. - Overview
- Exhibit 126: Glenmark Pharmaceuticals Ltd. - Product / Service
- Exhibit 127: Glenmark Pharmaceuticals Ltd. - Key offerings
- 10.10 Novartis AG
- Exhibit 128: Novartis AG - Overview
- Exhibit 129: Novartis AG - Business segments
- Exhibit 130: Novartis AG - Key offerings
- Exhibit 131: Novartis AG - Segment focus
- 10.11 Teva Pharmaceutical Industries Ltd.
- Exhibit 132: Teva Pharmaceutical Industries Ltd. - Overview
- Exhibit 133: Teva Pharmaceutical Industries Ltd. - Business segments
- Exhibit 134: Teva Pharmaceutical Industries Ltd. - Key news
- Exhibit 135: Teva Pharmaceutical Industries Ltd. - Key offerings
- Exhibit 136: Teva Pharmaceutical Industries Ltd. - Segment focus
- 10.12 Vertex Pharmaceuticals Inc.
- Exhibit 137: Vertex Pharmaceuticals Inc. - Overview
- Exhibit 138: Vertex Pharmaceuticals Inc. - Product / Service
- Exhibit 139: Vertex Pharmaceuticals Inc. - Key offerings
11 Appendix
- 11.1 Scope of the report
- 11.2 Inclusions and exclusions checklist
- Exhibit 140: Inclusions checklist
- Exhibit 141: Exclusions checklist
- 11.3 Currency conversion rates for US$
- Exhibit 142: Currency conversion rates for US$
- 11.4 Research methodology
- Exhibit 143: Research methodology
- Exhibit 144: Validation techniques employed for market sizing
- Exhibit 145: Information sources
- 11.5 List of abbreviations
- Exhibit 146: List of abbreviations
Research Framework
Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.
INFORMATION SOURCES
Primary sources
- Manufacturers and suppliers
- Channel partners
- Industry experts
- Strategic decision makers
Secondary sources
- Industry journals and periodicals
- Government data
- Financial reports of key industry players
- Historical data
- Press releases
DATA ANALYSIS
Data Synthesis
- Collation of data
- Estimation of key figures
- Analysis of derived insights
Data Validation
- Triangulation with data models
- Reference against proprietary databases
- Corroboration with industry experts
REPORT WRITING
Qualitative
- Market drivers
- Market challenges
- Market trends
- Five forces analysis
Quantitative
- Market size and forecast
- Market segmentation
- Geographical insights
- Competitive landscape
Frequently Asked Questions?
- US
- Canada
- Germany
- UK
- China
- Need for sustainable and safe respiratory drugs
- High cost of respiratory disease management
Key Questions Answered
- What are the key global market and the regional market share?
- What are the revenue-generating key market segments?
- What are the key factors driving and challenging this market’s growth?
- Who are the key market vendors and their growth strategies?
- What are the latest trends influencing the growth of this market?
- What are the variables influencing the market growth in the primary regions?
- What are the factors influencing the growth of the parent market?
Why should you prefer Technavio's market insights report?
Certified ISO 9001 : 2015
We are ISO 9001:2015 recognized that ensures quality services and product delivery to our clients.
We are GDPR and CCPA compliant! Your transaction & personal information is protected from unauthorized use.
Single:
One user only.
Quick & easy download optionEnterprise:
Unlimited user access (Within your organization)
Complimentary Customization Included
2500 USD
Get the report (PDF) sent to your email within minutes.
Subscribe & Save
Get lifetime access to our
Technavio Insights
Did you know?
Did you know?
Did you know?
Customized Report as per your Business Needs
- Our analysts will work directly with you and understand your needs
- Get data on specified regions or segments, competitor and Vendors
- Data will be formatted and presented as per your requirements
- We offer $1000 worth of FREE customization at the time of purchase
Let us help you make report more suited to your requirements.
- Get a competitive breakdown as per your niche industry
- Customize the data with various metrics that meet your business prerequisite
- Understand Revenue Sources, Customers and many more
- Details on Market Share
- These customizations are done in a short amount of time by our analysts and industry experts
